Brentuximab a novel antibody therapy: real‐world use confirms efficacy and tolerability for CD30‐positive cutaneous lymphoma

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith et al. · Journal of Clinical Oncology · 2012 · 1.5K citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Anas Younes, Nancy L. Bartlett, John P. Leonard et al. · New England Journal of Medicine · 2010 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 580 citations

Medicine, Hematology, Oncology +12

Results of a Phase II Trial of Brentuximab Vedotin for CD30⁺ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis

Madeleine Duvic, Michael T. Tetzlaff, Pamela Gangar et al. · Journal of Clinical Oncology · 2015 · 297 citations

Medicine, Immunology, Oncology +17

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

Youn H. Kim, Mahkam Tavallaee, Uma Sundram et al. · Journal of Clinical Oncology · 2015 · 281 citations · Full text

Medicine, Hematology, Oncology +17